Literature DB >> 16565101

Severe adverse reactions prompt call for trial design changes.

Susan Mayor.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 16565101      PMCID: PMC1410899          DOI: 10.1136/bmj.332.7543.683

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  7 in total

1.  Inquiry into adverse events in trial blames drug, not study design.

Authors:  Susan Mayor
Journal:  BMJ       Date:  2006-04-15

2.  Agency criticises drug trial.

Authors:  Michael Day
Journal:  BMJ       Date:  2006-06-03

3.  Immunomodulation strategies for preventing vascular disease of the brain and heart: workshop summary.

Authors:  John Hallenbeck; Gregory Del Zoppo; Tom Jacobs; Antoine Hakim; Stephen Goldman; Ursula Utz; Ahmed Hasan
Journal:  Stroke       Date:  2006-11-02       Impact factor: 7.914

4.  Social, cultural and ethical aspects of drug use -- changes over 40 years: a personal look back.

Authors:  Andrew Herxheimer; Emilio Sanz
Journal:  Eur J Clin Pharmacol       Date:  2008-01-03       Impact factor: 2.953

5.  Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.

Authors:  Wilco de Jager; Esther P A H Hoppenreijs; Nico M Wulffraat; Lucy R Wedderburn; Wietse Kuis; Berent J Prakken
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

Review 6.  [Concepts on the pathogenesis of juvenile idiopathic arthritis].

Authors:  T Niehues; O Feyen; T Telieps
Journal:  Z Rheumatol       Date:  2008-03       Impact factor: 1.372

7.  Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays.

Authors:  Wilco de Jager; Katarzyna Bourcier; Ger T Rijkers; Berent J Prakken; Vicki Seyfert-Margolis
Journal:  BMC Immunol       Date:  2009-09-28       Impact factor: 3.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.